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Background: Clinical and therapeutic patterns of ulcerative co-
litis (UC) are variable in different world regions. The purpose of
this study was to examine two close independent southern Euro-
pean UC populations from 2 bordering countries and observe how
demographic and clinical characteristics of patients can inﬂuence
the severity of UC.
Methods: A cross-sectional study was conducted during a 15-
month period (September 2005 to December 2006) based on data
of 2 Web registries of UC patients. Patients were stratiﬁed
according to the Montreal Classiﬁcation and disease severity was
deﬁned by the type of treatment taken.
Results: A total of 1549 UC patients were included, 1008 (65%)
from northern Portugal and 541 (35%) from Galicia (northwest
Spain). A female predominance (57%) was observed in Portu-
guese patients (P < 0.001). The median age at diagnosis was 35
years and median years of disease was 7. The majority of patients
(53%) were treated only with mesalamine, while 15% had taken
immunosuppressant drugs, and 3% biologic treatment. Most
patients in both groups were not at risk for aggressive therapy.
Extensive colitis was a predictive risk factor for immunosuppres-
sion in northern Portugal and Galicia (odds ratio [OR] 2.737,
95% conﬁdence interval [CI]: 1.846–4.058; OR 5.799, 95% CI:
3.433–9.795, respectively) and biologic treatment in Galicia (OR
6.329, 95% CI: 2.641–15.166). Younger patients presented a
severe course at onset with more frequent use of immunosuppres-
sors in both countries.
Conclusions: In a large population of UC patients from two in-
dependent southern European countries, most patients did not
require aggressive therapy, but extensive colitis was a clear risk
factor for more severe disease.
(Inﬂamm Bowel Dis 2010;16:1227–1238)
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T he incidence and prevalence of ulcerative colitis (UC)are very variable in different countries. In Shivananda’s
et al’s classic study,1 a north–south gradient was detected in
European countries, with a lower incidence of inﬂammatory
bowel disease (IBD) in southern countries such as Portugal
and Spain. In the last decades this difference has diminished,
possibly because of notable advances of health resources in
both countries, and currently both Iberian nations are consid-
ered as having a mid-level prevalence of UC, with gradual
propensity toward the higher level group.2,3
There are insufﬁcient data heretofore comparing differ-
ent geographical populations of patients with UC regarding
disease severity; additionally, most of these studies compared
either close populations in the same country4 or populations
with very different geographical and genetic characteristics.5
The allocation of patients into major categories, such as the
Montreal Classiﬁcation,6 makes this approach possible.
Northern Portugal and Galicia (northwest Spain) are
two proximate areas that have been politically separated
for the last six centuries. Despite this political separation,
the populations have maintained a strong contact due to
similar languages, cultures, and traditions.
The aim of this study was to compare two independent
geographically and genetically close UC populations from
two different countries and analyze how demographic and
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clinical characteristics of patients may affect the severity of
UC.
MATERIALS AND METHODS
Patient Inclusion
During a 15-month period (September 2005 to De-
cember 2006), Portuguese doctors following patients with
IBD had the opportunity to collect clinical data and send it
to a central database via the Internet (http://www.
gedi2005.med.up.pt/). Patient registration was carried out
through a Web-based system with password and user name
validated by a scientiﬁc committee. The database was
approved by national authorities and was supported by the
Portuguese group of studies of IBD (GEDII: http:/www.
gedii.med.up.pt). From these subjects only those from
northern Portugal were chosen, thereby including all
patients from hospitals situated north of the Douro River
(Fig. 1). Twenty-one doctors participated in the study. UC
patients were included from 2 third-level hospitals (Sa˜o
Joa˜o Hospital of Porto and Santo Anto´nio Hospital of
Porto) (55%), from 4 second-level hospitals (Guimara˜es,
Paredes, Vila Real, and Braga Hospitals) (44.5%), and
patients from private physicians (0.5%). Many ﬁrst- and
second-level hospitals refer their patients to third-level
medical centers.
Concurrently, Galician doctors following patients with
IBD had the opportunity to collect clinical data and send it to
a central database via the Internet (http://www.alceingenieria.
net). Patient registration was processed through a Web-based
system with password and user name validated by a scientiﬁc
committee. The database was supported by the Galician group
of studies of IBD (EIGA). Patients from Galicia (Spain) (Fig.
1) were included from 4 reference hospitals (University Hos-
pital of Santiago, Complexo Hospitalario of Pontevedra,
Arquitecto Marcide Hospital from Ferrol, and Xeral Cı´es Hos-
pital from Vigo). No patients from private practices were
included. These 4 hospitals have IBD units and are all third-
level centers, receiving patients from smaller centers (Comar-
cal Hospitals, i.e., ﬁrst- or second-level hospitals).
Spain and Portugal have very similar healthcare sys-
tems. Both countries have public universal healthcare systems
and all Spanish and Portuguese citizens have free access to
healthcare provided by the National Health Services (NHS).7,8
The information used to complete the data was
obtained from clinical charts during a routine medical ex-
amination. Several reunions between members of both
countries were organized to standardize and clarify the dif-
ferent parameters used. The diagnostic criteria for UC were
based on a suggestive clinical history associated with endo-
scopic and histological signs of inﬂammation of the mu-
cosa, after excluding infectious disease by culture and mi-
croscopic stool examination.
Data Collection
For each patient several parameters were collected:
date and age of diagnosis onset, disease extent, family his-
tory of IBD, extraintestinal manifestations, use and response
to steroids, immunosuppression, biologic treatment, and
need for surgery. Only patients who underwent colectomy or
proctocolectomy were considered as being submitted to ab-
dominal surgery. The extent of lesions, that is, the most
proximal level achieved at any time since the diagnosis, was
measured and patients were classiﬁed as proctitis, left-sided,
and extensive colitis.6 Age at diagnosis was divided into 3
groups (16 years, 17–40 years, and >40 years). In relation
to steroids, only oral or intravenous forms were taken into
consideration and steroid resistance was presumed when
patients maintained active disease despite a prednisolone
dose up to 1 mg/kg/day over a 2-week period. Steroid-de-
pendent disease was stipulated as the inability to taper ste-
roids below the equivalent of 10 mg/day of prednisolone
without recurrence of active disease, or the need for a second
course of steroids in a 6-month period.
Disease Severity
Disease severity was deﬁned by the type of treatment
administered (adapted from Loftus et al9). Patients were
categorized into 3 different severity grades: Group 1 repre-
senting mild/moderate disease (patients with no treatment
or with salicylates, or episodic pulses of steroids without
steroid refraction or dependency), Group 2 for severe dis-
ease with drug-dependent or drug-refractory behavior
(patients treated with steroids, with steroid resistance or de-
pendency, or immunomodulators/biological) and Group 3
for patients with medically refractory disease, submitted to
surgery. In order to conﬁrm and attribute a stronger value
to the results, a second analysis was performed excluding
all UC patients with less than 5 years of diagnosed disease.
Statistics
Categorical variables were divided in absolute fre-
quencies (n) and relative frequencies (%). Means and
standard deviations (SDs) for continuous variables were
used if a normal distribution could be assumed, or median
and interquartile range (IQR: 25th to 75th percentile) if
normality could not be assumed. A Kolmogorov–Smirnov
test was used to test for normality.
When testing a hypothesis concerning continuous varia-
bles, nonparametric tests (Mann–Whitney and Kruskal–Wallis
tests) were used as appropriate, taking into account normality
assumptions and the number of groups compared. When test-
ing a hypothesis regarding categorical variables a chi-square
test and Fisher’s exact test were used, as appropriate. In order
to have a more thorough understanding of the factors associ-
ated with the use of immunosuppression and biologic treat-
ment, univariate and multivariate logistic regression modeling
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was used. In the multivariate logistic regression models the de-
pendent variables were immunosuppression and biologic treat-
ment. The model’s goodness-of-ﬁt was assessed using the
Hosmer–Lemeshow statistic. The signiﬁcance level used was
0.05. Statistical analysis was performed using the software Sta-
tistical Package for the Social Sciences v. 16.0 for Windows
(SPSS, Chicago, IL).
RESULTS
Global Demographic Characteristics
A total of 1549 UC patients were included, 1008 (65%)
from northern Portugal and 541 (35%) from Galicia (northwest
Spain). Overall, 721 (47%) were male and 828 (53%) female.
Median age at diagnosis was 35 years (percentile 25-26 and
percentile 75-46) and median years of disease was 7 (percentile
25-3 and percentile 75-11) (Table 1). When patients were clas-
siﬁed by age at diagnosis, 72 (5%) were diagnosed at 16 years
or below, 899 (59%) were diagnosed between 17 and 40 years,
and 558 (36%) were diagnosed over 40 years (Table 1). An
analysis of age distribution did not show a second peak at the
age of 50–70 years (Fig. 2). Regarding classiﬁcation of disease
extent, the maximum limit and not extent at diagnosis was cho-
sen because previous studies showed that the initial extent did
not affect the subsequent disease activity course. Proctitis was
found in 449 (29%) patients (E1 in Montreal Classiﬁcation),
683 (44%) had left-sided colitis (E2 in Montreal Classiﬁcation),
and 415 (27%) had extensive colitis (E3 in Montreal Classiﬁca-
tion) (Table 2). When the patients were stratiﬁed in different
categories of disease duration it was possible to see some
changes over time. Concerning proctitis there was a decrease in
FIGURE 1. Map of the two regions where the UC popula-
tions were selected: Galica (A) (North West of Spain) and
North of Portugal (B). [Color figure can be viewed in the
online issue, which is available at www.interscience.wiley.
com.]
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frequency after 4 years of diagnosis, achieving a steady state
subsequently: 34% in those with less than 4 years of disease
and thereafter 30% (5–9 years of disease), 25% (10–14 years),
25% (15–19 years), and 28% (more than 19 years). In both
populations there was a rise in the frequency of left-sided coli-
tis in the patients with more than 4 years of diagnosis (44%,
46%, 49%, and 45%, at 5–9, 10–14, 15–19, and more than 19
years after diagnosis, respectively) in comparison to those with
a more recent diagnoses (until 4 years, 41%). In extensive coli-
tis there was no change over time (25%, 25%, 28%, 24%, and
24%, at 5–9, 10–14, 15–19, and more than 19 years after diag-
nosis, respectively). That is, in our population after the fourth
year of disease the variation in terms of location was not worth
mentioning. A family history of IBD was detected in 140
patients (11%) and 256 patients (17%) had extraintestinal man-
ifestations (Table 2). After analyzing treatment characteristics
it was found that 72 (5%) patients had developed steroid-resist-
ance and 195 (14%) steroid-dependency (Table 2). Regarding
the use of more advanced drugs, it was observed that 227
(15%) patients had taken immunosuppressant drugs and 48
(3%) biologic treatment (Table 2).
Comparison Between Populations According to
Age at Diagnosis
Important differences were shown in demographic
characteristics between patients from Portugal and Galicia
(Table 1). Considering gender distribution, in Portugal most
patients were female (57%), while in Galicia only 48% were
of this gender (P < 0.001). Nevertheless, when the popula-
tion was stratiﬁed by age, gender differences were found
only in patients diagnosed above 40 years, where there was
a signiﬁcant predominance of female patients in the Portu-
guese group of patients (53%) compared to the Galician
group (40%) (P ¼ 0.003). Concerning age at presentation,
no signiﬁcant differences in the percentage of patients diag-
nosed before 16 years of age were observed, contrary to data
found in the older population (>40 years), where the Gali-
cian population was signiﬁcantly older (52%) at diagnosis
when compared to the Portuguese (50%) (P ¼ 0.028).
After applying the Montreal Classiﬁcation for disease
extent (Table 2), the most common type was E2 (left-sided
colitis). In the Galician group there was a predominance of
proctitis, while extensive colitis was more common among
Portuguese patients, the latter being particularly evident in
the older group (>40 years). Regarding treatment patterns,
more steroid-resistant and steroid-dependant patients were
found in the Galician group of patients and subsequently
more immunosuppression and biologic treatment were
applied in those diagnosed in the intermediate age group
(17–40 years) (Table 2).
Severity
Regarding severity, notably 53% of patients did not
need steroids, 16% had taken steroids without more drugs
supplied, and 75% were not submitted to immunosuppres-
sion, biologicals, or surgery (Table 3). Nonetheless, there
was a trend toward steroid-dependency and the use of
immunosuppression or biologicals in the Galician group
compared to northern Portugal in all age groups (Fig. 3B).
Contrariwise, in Portugal an inclination toward surgery was
observed at all ages in comparison with the Galician group
(Fig. 3B).
Although differences in severity in the proctitis (E1)
group were not observed among the different populations,
in left-sided colitis (E2) there was a trend toward
FIGURE 2. Frequency of age at diagnosis in North of Portu-
gal (A) and Galica (B).
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immunosuppression in Galician patients, while a propensity
toward surgery was detected in Portuguese patients (Fig.
3A). This trend was more noteworthy in patients of the E3
group (Fig. 3A). Remarkably, an overwhelmingly large
percentage of patients in the proctitis group did not require
treatment with immunomodulators or biologicals (98%),
contrary to the extensive colitis population, where 25%
were solely treated with mesalamine.
Concerning age of onset, those diagnosed before 16
years had a more aggressive initial course in Portugal and
in Galicia requiring more steroids (51% and 40%, respec-
tively, in northern Portugal and Galicia) and immunomodu-
lators (26 and 35%, respectively in northern Portugal and
Galicia). In order to highlight age onset, patients were
stratiﬁed in more categories than those found in the Mon-
treal Classiﬁcation: 41–50 years, 51–60 years, and more
than 60 years. In northern Portugal the severity curve drops
until 40 years at disease onset, ﬂattening thereafter. In
Galicia the same behavior was detected until 40 years of
disease onset; however, the curve continues to drop (Fig.
4A,B).
Furthermore, considering the 3 grades of disease se-
verity, a tendency for increasing severity was found among
patients with disease duration of 0–10 years, primarily in
Galicia, followed by a slow descending gradient (Fig.
4C,D). However, emphasizing the low mean disease score
found is fundamental because it suggests that the majority
of the patients had mild disease.
Comparing Populations with Less Than and More
Than 5 Years of Diagnosed Disease
In order to emphasize the results, as previously done
in CD in the Montreal Classiﬁcation, patients with 5 or
less years of diagnosed UC were excluded to detect if the
results observed were maintained. By excluding these
patients, the cohort was reduced to 960 UC patients, 645
(67%) from northern Portugal and 315 (33%) from Galicia
(Table 4). When comparing patients with less than 5 years
or 5 or more years of disease no differences were found in
Portugal or in Spain in relation to age distribution. Regard-
ing disease location, in Portugal there was a larger percent-
age of patients with proctitis in the less than 5 years group,
in contrast to the extensive colitis group, which remained
constant in time. Concerning disease severity, many
patients in Portugal and in Spain did not require aggressive
therapy, regardless of the disease duration (Fig. 5). Never-
theless, there was a clear trend toward immunosuppression
in extensive colitis patients in those with 5 or more years
of disease (Fig. 5A). The same trend was observed in Gali-
cian patients diagnosed before age 16 years (Fig. 5B).
TABLE 2. Clinical Characteristics Comparing UC Patients from Northern Portugal and Galicia (Global and Adjusted by
Age at Diagnosis)
Age at Diagnosis
16 years 17–40 years >40 years Total
Northern
Portugal Galicia P
Northern
Portugal Galicia P
Northern
Portugal Galicia P
Northern
Portugal Galicia
Extent of disease, n (%)
Proctitis 8 (17) 5 (19) 0.976a 173 (28) 101 (36) 0.056a 77 (24) 79 (33) <0.001a 263 (26) 186 (34)
Left-sided
colitis
15 (33) 8 (31) 262 (42) 117 (42) 151 (47) 120 (51) 438 (44) 245 (45)
Extensive
colitis
23 (50) 13 (50) 186 (30) 59 (21) 94 (29) 37 (16) 305 (30) 110 (20)
E.I.M., n (%) 12 (26) 3 (12) 0.144 110 (18) 52 (19) 0.743a 39 (12) 37 (16) 0.225a 164 (16) 92 (17)
Steroid
resistance, n (%)
1 (2) 1 (4) 0.745c 23 (5) 23 (8) 0.030a 8 (3) 15 (6) 0.106a 32 (4) 40 (7)
Steroid
dependency, n (%)
8 (20) 6 (23) 0.727 59 (11) 52 (19) 0.002a 32 (12) 36 (15) 0.285a 100 (12) 95 (18)
Immunosupression,
n (%)
12 (26) 9 (35) 0.444 81 (13) 53 (19) 0.019a 38 (12) 32 (14) 0.536a 132 (13) 95 (18)
Biologic
treatment, n (%)
2 (4) 2 (8) 0.620c 15 (2) 17 (6) 0.006a 1 (0) 10 (4) 0.001b 18 (2) 30 (6)
E.I.M., extraintestinal manifestations.
aChi-square test.
bMann-Whitney test.
cFisher’s exact test.
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Univariate and Multivariate Analysis of Factors
Associated with Immunosuppression, Biological
Treatment, and Abdominal Surgery
Table 5 shows the variables associated with the use
of immunosuppressants and biologic therapy on uni- and
multivariate analysis. Extensive colitis was clearly a pre-
dictive risk factor for immunosuppression in northern Por-
tugal and in Galicia (Table 5) and biologic therapy in Gali-
cia (odds ratio [OR] 6.329; 95% conﬁdence interval [CI]:
2.641–15.166). In relation to age, the older Portuguese
group (>40 years) was at a signiﬁcantly lower risk for bio-
logic treatment (OR 0.067; 95% CI: 0.007–0.893) when
compared to younger groups, as opposed to the Galician
population, where no evident differences were found con-
cerning age.
DISCUSSION
Northern Portugal and Galicia (northwest Spain) are
two contiguous areas with similar extents separated by the
river Min˜o. Although politically separated, these areas
share some characteristics besides genetics, culture, and
language, such as climate, geographic distribution of the
population in rural areas, and similar food habits (high ﬁsh
and shellﬁsh consumption).
A comparative cross-sectional study of two popula-
tions was performed; the intention was not to perform an
epidemiological study. Some previous series had compared
different populations from different countries like the Euro-
pean Collaborative Study on Inﬂammatory Bowel Disease
(EC-IBD),1,10,11 and others that compared different areas
from the same country4,12,13 or different ethnic groups in
the same area.14 Notwithstanding, few have directly com-
pared populations from different countries and those that
exist were restricted to nonbordering nation populations15
or new data with others previously published.16 To our
knowledge, this is the ﬁrst study comparing two genetically
close populations from bordering countries.
Regarding family history rate or the presence of
extraintestinal manifestations, no differences were observed
between the two groups. The family history rate observed
was 10%, similar to that found in similar publications,17 as
well as the occurrence of extraintestinal manifestations.18,19
Concerning gender, in Portugal a female predominance was
detected (57%). In the majority of UC studies no gender
differences were reported,20–22 although similar results as
found in the northern Portuguese group of patients have
been previously mentioned.23,24 Furthermore, in the Gali-
cian group diagnosed over 40 years there was a predomi-
nance of males, a fact found in a previous Canadian25 and
EC-IBD studies,1 where gender divergence at older ages
was seen, consistent with a dramatic decline of new diag-
noses in women after the third decade. In relation to age of
onset of UC a second peak was not detected. This is in
conformity with recent studies in which a second peak was
not apparent. Whether this reﬂects a real change in the pat-
tern or is due to recent larger and more scientiﬁcally sound
studies remains uncertain.26
In the Galician group there were more patients with
proctitis (34% versus 26%) and less extensive colitis (20%
versus 30%), a fact logically related with a higher number of
older diagnosis patients in Galicia. In concordance, a higher
rate of proctitis in elderly UC has also been reported.27
In the IBSEN study28 the majority (78%) of patients
did not use systemic steroids during the second 5-year
TABLE 3. Classification of UC According to Severity Score
Disease Severity
1 2 3
Pan (%) n (%) n (%)
Age at diagnosis, n (%)
16 years 44 (76) 11 (19) 3 (5) 0.263
17-40 years 673 (85) 90 (11) 32 (4)
>40 years 442 (87) 50 (10) 18 (4)
Extent of disease, n (%)
Proctitis 408 (99) 4 (1) 2 (0) <0.001
Left-sided colitis 538 (87) 64 (10) 17 (3)
Extensive colitis 223 (65) 85 (25) 35 (10)
aChi-square test.
Disease severity was deﬁned by the type of treatment administered (adapted from Loftus et al10). Patients were categorized into 4 different severity grades:
group 1 representing mild/moderate disease (patients with no treatment or with salicylates, or episodic pulses of steroids without steroid refraction or de-
pendency), group 2 for severe disease with drug-dependent or drug-refractory behavior (patients treated with steroids, with steroid resistance or depend-
ency, or immunomodulators/biological), and group 3 for patients with medical refractory disease, submitted to surgery.
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period and, according to patient perceptions, remission or
mild symptoms after initial activity represented the most
common course, while chronic continuous symptoms were
rare. Our data support this observation because after 10
years of disease there is a progressive decline in disease se-
verity and overall the mean score is low. Likewise, 53% of
patients did not need steroids, and 75% were not submitted
to immunosuppression, biologicals, or surgery, revealing a
mild clinical behavior. This observation is crucial because
an overwhelmingly large percentage of patients in the proc-
titis group did not require treatment with immunomodula-
tors or biologicals (90%), reinforcing the importance of sal-
icylates in UC. Moreover, and in contrast to recent series
from countries traditionally reported as regions of low inci-
dence and milder disease,29 15% of the patients needed
immunosuppressors and 3% were submitted to surgery. In
the Galician population there was a higher rate of steroid-
dependency and steroid-resistance. No clear explanation
was found to justify this disparity, particularly considering
that both the Galician and northern Portuguese rates are
lower than those described in classic studies.30 One could
speculate that this could be due to the relatively low me-
dian of years after diagnosis; however, after excluding
patients with 5 or less years since diagnosis, the percen-
tages were only slightly changed. In relation to surgical
needs, the colectomy rate was lower than most previously
reported,31 but comparable to ﬁgures from the European
multicenter study,32 especially for the southern European
centers included (3.9% at 10 years).
The most substantial difference in this study is the
higher use of immunosuppressants and biological therapies
among Galician patients. Once conﬁrmed that patients
from both countries resembled each other regarding health-
care access (Portugal and Spain NHS have free access) and
did not have substantial differences concerning medication
prices,8 this difference could be attributed to the higher
FIGURE 3. Distribution of severity of UC defined by type of treatment administered (adapted from Loftus et al) (10) accord-
ing to extension of colitis (A) and age at diagnosis onset (B). Patients were categorized into three different severity grades:
group 1 representing mild/moderate disease (patients with no treatment or with salicylates, or episodic pulses of steroids
without steroid refraction or dependency), group 2 for severe diesase with drug-dependent or drug-refractory behaviour
(patients treated with steroids, with steroid resistance or dependency, or immunomodulators/biological) and group 3 for
patients with medical refractory disease, submitted to surgery.
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rate of steroid-dependency and resistance in these patients
or could plausibly be explained by the fact that the Gali-
cian patients are treated in IBD units, where physicians and
nurses are more experienced with the use of more aggres-
sive drugs,33,34 leading to an earlier introduction in a ‘‘top-
down’’35 or accelerated strategy. In this context, in northern
Portugal the proportion of patients taking immunosuppres-
sants and biologics was lower, especially in those with
extensive colitis, than that found in Galicia, but colectomy
rates were higher. At the present, the dearth of prospective
studies in UC does not support the tendency of early intro-
duction of immunosuppressors and biologics36 as shown in
the SONIC study in CD.37
In this study, stratifying for the variable age of dis-
ease onset as the Montreal Classiﬁcation for CD, younger
patients seem to have a more aggressive initial course with
a greater need for steroids and immunosuppressants. In
addition, among the elderly a notably lower severity index
was found, suggesting a decline in severity in this popula-
tion as interpreted from the decrease in number of exacer-
bations, regression in extension of the inﬂammatory
lesions, colectomy requirements, and risk of colorectal can-
cer as previously reported.38–40 This evidence could be
helpful for future classiﬁcation of UC, indicating that a
more meaningful age division may be set at 60 years, strat-
ifying patients above this age as elderly colitis. This obser-
vation was previously found in the IBSEN study,28 sug-
gesting that the course of UC becomes milder with
increasing age, and that the initial age should be detached
from the clinical classiﬁcation of patients. Moreover, in
both populations extensive colitis was a risk factor for
immunosuppression, in concordance with two recent se-
ries.41,42 In relation to biologics, there is a paucity of infor-
mation in UC, although in this study extensive colitis was
related to biologic treatment in Galicia. This fact is sup-
ported by indirect data which associated more extensive
disease with an increased risk for colectomy,32 emphasiz-
ing disease extent as a biological marker.43
FIGURE 4. Disease severity (median and 25th and 75th percentiles) in different intervals of age of onset and intervals of dis-
ease duration. The disease severity index was classified in 3 caterories defined by the type of treatment administered
(adapted from Loftus et al9).
Inﬂamm Bowel Dis  Volume 16, Number 7, July 2010Barreiro-de Acosta et al
1234
TABLE 4. Comparison of Northern Portugal and Galicia Populations with Less Than 5 or More Than 5 Years at
Diagnosis According to Gender, Age, and Disease Extent
Northern Portugal Galicia
<5 years 5 years Pa <5 years 5 years Pa
Gender, n (%)
Male 175 (50) 259 (40) 0.004 118 (52) 166 (53) 0.954
Female 177 (50) 386 (60) 107 (48) 149 (47)
Age at diagnosis, n (%)
16 years 16 (5) 30 (5) 0.105 8 (4) 18 (6) 0.255
17-40 years 204 (59) 418 (65) 110 (49) 167 (53)
>40 years 128 (37) 194 (30) 106 (47) 130 (41)
Age, median (P25-P75) 36 (27–45) 33 (25–43) 0.004b 36 (27–45) 33 (25–43) 0.072b
Extent of disease, n (%)
Proctitis 108 (31) 151 (23) 0.010 83 (37) 102 (32) 0.359
Left-sided colitis 132 (38) 301 (47) 102 (45) 143 (45)
Extensive colitis 111 (32) 192 (30) 40 (18) 70 (22)
aChi-square test.
bMann-Whitney test.
FIGURE 5. Distribution of severity of UC defined by type of treatment administered (adapted from Loftus et al9) according
to extension of colitis (A) and age at diagnosis onset (B) adjusted by length of disease diagnosed (cut off of five years).
Patients were categorized into three different severity grades: group 1 representing mild/moderate disease (patients with no
treatment or with salicylates, or episodic pulses of steroids without steroid refraction or dependency), group 2 for severe dis-
ease with drug-dependent or drug-refractory behaviour (patients treated with steroids, with steroid resistance or depend-
ency, or immunomodulators/biological) and group 3 for patients with medical refractory disease, submitted to surgery.
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In CD the applicability of the Montreal Classiﬁcation
is only considered accurate in patients with 5 or more years
of disease onset, because there is a minimum time of evo-
lution before classifying behavior.44 In relation to UC
patients some qualms persist. In order to elucidate this
issue, regarding major clinical characteristics and disease
severity, the patients of each country were compared in
terms of disease duration in both groups, namely, patients
with less or more than 5 years. In this respect, in Portugal
there were a larger percentage of patients with proctitis in
patients with less than 5 years, while in the extensive coli-
tis group the proportion of patients was constant over time.
Longitudinal ﬂuctuation of disease extent has been
described45 and in Portugal a proximal spread from procti-
tis is perceived to exist. Concerning disease severity, there
was a trend toward immunosuppression and surgery in
those patients with 5 or more years of disease in extensive
colitis; on the other hand, in proctitis and left-sided colitis
the severity was immutable over time. Regarding age of
disease onset, those diagnosed before 16 years have a more
severe initial course in Portugal and Galicia; however, in
Portugal this tendency was lost in patients with more than
5 years of disease. A more timely immunosuppression
intervention made by pediatricians in the past years in Por-
tugal in light of the latest knowledge suggesting early
introduction of immunosuppression in pediatric patients,46
or by disease severity lessening over time could explain
this.
This study presents some limitations. First, it was a
cross-sectional study. Second, two different databases were
used and crossed, and consequently some differences in
data collection could not have been avoided. Notwithstand-
ing, one must stress that several meetings took place in
order to unify criteria and explain the aims of the work. In
addition, most of gastroenterologists involved were senior
gastroenterologists with IBD differentiation, and in Galicia
all of them worked in IBD units.
In conclusion, despite some clinical differences, in a
large population of UC patients of two independent south-
ern European countries most patients did not need aggres-
sive therapy, and extensive colitis was a clear risk factor
for more severe disease. Furthermore, patients diagnosed
before 16 years seem to have a more severe initial course,
with a greater need for steroids and immunosuppressants.
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